高脂質血症患者に対するCholestyramineの長期投与による効果

J-STAGE
  • 松沢 佑次
    The Second Department of Internal Medicine, Osaka University, Medical School
  • 山本 章
    The Department of Etiology and Pathophysiology, National Cardiovascular Center Research Institute
  • 山村 卓
    The Department of Etiology and Pathophysiology, National Cardiovascular Center Research Institute
  • 洪 秀樹
    The Department of Internal Medicine, National Cardiovascular Center
  • 假屋 純人
    The Department of Internal Medicine, National Cardiovascular Center
  • 南部 征喜
    The Department of Internal Medicine, National Cardiovascular Center
  • 石川 勝憲
    The Second Department of Internal Medicine, Osaka University, Medical School
  • 首藤 弘史
    The Second Department of Internal Medicine, Osaka University, Medical School
  • 垂井 清一郎
    The Second Department of Internal Medicine, Osaka University, Medical School
  • 中田 良和
    The Diabetes Center, Osaka National Hospita
  • 泉 寛治
    The Diabetes Center, Osaka National Hospita
  • 秋岡 壽
    The First Department of Internal Medicine, Nissei Hospital
  • 林 勝
    The First Department of Internal Medicine, Nissei Hospital
  • 大石 まり子
    The Department of Internal Medicine, Kyoto National Hospital
  • 小出 操子
    The Department of Internal Medicine, Kyoto National Hospital
  • 赤澤 好温
    The Department of Internal Medicine, Kyoto National Hospital
  • 樋口 勝
    The Third Department of Internal Medicine, Nara Medical University
  • 辻井 正
    The Third Department of Internal Medicine, Nara Medical University
  • 上田 賀美
    The Department of Internal Medicine, Wakayama Medical College
  • 猪尾 和弘
    The Department of Internal Medicine, Wakayama Medical College
  • 宮村 敬
    The Department of Internal Medicine, Wakayama Medical College
  • 奥野 魏一
    The Department of Internal Medicine, Itami City Hospital
  • 和田 正明
    The Fourth Department of Internal Medicine, Hyogo College of Medicine
  • 鹿野 真勝
    The Fourth Department of Internal Medicine, Hyogo College of Medicine
  • 下山 孝
    The Fourth Department of Internal Medicine, Hyogo College of Medicine
  • 高野 新二
    The First Department of Internal Medicine, Kobe University School of Medicine
  • 岡本 良三
    The First Department of Internal Medicine, Kobe University School of Medicine
  • 福崎 恒
    The First Department of Internal Medicine, Kobe University School of Medicine
  • 上野山 林造
    The Second Department of Internal Medicine, Kobe University School of Medicine
  • 生野 哲雄
    The Second Department of Internal Medicine, Kobe University School of Medicine
  • 老籾 宗忠
    The Second Department of Internal Medicine, Kobe University School of Medicine
  • 馬場 茂明
    The Second Department of Internal Medicine, Kobe University School of Medicine
  • 池田 敏
    The First Department of Internal Medicine, Okayama University, Medical School
  • 武田 和久
    The First Department of Internal Medicine, Okayama University, Medical School
  • 長島 秀夫
    The First Department of Internal Medicine, Okayama University, Medical School
  • 遠藤 浩
    The Department of Internal Medicine, Kurashiki Central Hospital
  • 山本 晋一郎
    The Department of Internal Medicine, Kawasaki Medical School
  • 平野 寛
    The Department of Internal Medicine, Kawasaki Medical School
  • 梶山 梧朗
    The First Department of Internal Medicine, Hiroshima University, School of Medicine
  • 和田 一成
    The Second Department of Internal Medicine, Yamaguchi University, School of Medicine
  • 楠川 禮造
    The Second Department of Internal Medicine, Yamaguchi University, School of Medicine
  • 赤松 興一
    The Third Department of Internal Medicine, Ehime University School of Medicine
  • 太田 康幸
    The Third Department of Internal Medicine, Ehime University School of Medicine
  • 古賀 俊逸
    The Third Department of Internal Medicine, Faculty of Medicine, Kyushu University
  • 佐田 禎造
    The Second Department of Internal Medicine, School of Medicine, Fukuoka University
  • 荒川 規矩男
    The Second Department of Internal Medicine, School of Medicine, Fukuoka University
  • 植木 一虎
    The Third Department of Internal Medicine, Kurume University, School of Medicine
  • 戸嶋 裕徳
    The Third Department of Internal Medicine, Kurume University, School of Medicine
  • 中村 〓久
    The Department of Internal Medicine, Institute of Constitutional Medicine, Kumamoto University
  • 鵜澤 春生
    The Department of Internal Medicine, Institute of Constitutional Medicine, Kumamoto University
  • 諸冨 康行
    The First Department of Internal Medicine, Miyazaki Medical College
  • 児玉 健二
    The First Department of Internal Medicine, Miyazaki Medical College
  • 田仲 謙次郎
    The First Department of Internal Medicine, Miyazaki Medical College

書誌事項

タイトル別名
  • The Effect of Cholestyramine in Hyperlipidemic Patients under Long-Term Therapy

抄録

Long-term therapy with cholestyramine, a strong basic anion exchange resin, involving 168 cases of type II hyperlipidemic patients resulted in the following observations:<br>1) The lowering of the serum total cholesterol (TC) level was seen in the second week of the cholestyramine therapy and the statistically significant decrease lasted for the entire 52-week administration period thereafter. The mean reduction rate of TC during the therapy was 14.6% overall.<br>2) No difference was noted in TC lowering effect of cholestyramine between the group at daily dosage of 8g (109 cases) and the group at daily dosage of 12g (59 cases). Thus the daily dosage of 8g taken twice a day was confirmed to be more beneficial considering the facile administration schedule.<br>3) No difference in drug efficacy was observed between the 91 cases of type IIa and the 77 cases of type IIb hyperlipidemic patients, and larger rate of decrease was obtained in the group with higher TC levels at pretherapy. The drug was also comfirmed to be effective with familial hypercholesterolemia.<br>4) During the therapy, serum triglyceride and HDL-cholesterol levels tended to increase, while β-lipoprotein and phospholipid levels slightly decreased.<br>5) The most frequent side effects were gastrointestinal symptoms such as constipation and abdominal distention, and in most cases continuation of the therapy was possible. In a few cases, increases of serum GOT and GPT levels manifested, but most of them were of minor nature.<br>In conclusion, cholestyramine is considered to be a safe and highly beneficial drug even against serious cases of type II hyperlipidemic patients including familial hypercholesterolemic patients who have been considered difficult to cure.

収録刊行物

  • 動脈硬化

    動脈硬化 11 (3), 693-711, 1983

    Japan Atherosclerosis Society

詳細情報 詳細情報について

問題の指摘

ページトップへ